{
    "clinical_study": {
        "@rank": "9919", 
        "acronym": "PP-02", 
        "arm_group": [
            {
                "arm_group_label": "Iron isomaltoside 1000", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min."
            }, 
            {
                "arm_group_label": "Red blood cell transfusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Allogenic RBC transfusion is dosed to trigger Hb:\nWomen with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC\nWomen with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to get explorative information about IV high single\n      dose infusion of iron isomaltoside 1000 compared to RBC transfusion in the treatment of\n      severe PP-IDA evaluated as physical fatigue"
        }, 
        "brief_title": "Treatment of Women After Severe Postpartum Haemorrhage", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Postpartum Haemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. PPH > 1000 mL\n\n          2. Hb \u2265 5.5 and \u2264 8.0 g/dL (\u2265 3.5 and \u2264 5.0 mmol/L)\n\n          3. Willingness to participate and signed the informed consent form\n\n        Exclusion Criteria:\n\n          1. Women aged < 18 years\n\n          2. Multiple births\n\n          3. Peripartum RBC transfusion\n\n          4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and\n             haemosiderosis)\n\n          5. Known hypersensitivity to parenteral iron or any excipients in the investigational\n             drug products\n\n          6. Women with a history of active asthma within the last 5 years or a history of\n             multiple allergies\n\n          7. Known decompensated liver cirrhosis and active hepatitis\n\n          8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome\n             (defined according to \"Dansk Selskab for Obstetrik og Gyn\u00e6kologi guidelines\")\n\n          9. Active acute infection assessed by clinical judgement\n\n         10. Rheumatoid arthritis with symptoms or signs of active joint inflammation\n\n         11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia\n             (known haematologic disorder other than iron deficiency)\n\n         12. Not able to read, speak and understand the Danish language\n\n         13. Participation in any other clinical study where the study drug has not passed 5\n             half-lives prior to the baseline\n\n         14. Any other medical condition that, in the opinion of Investigator, may cause the\n             patient to be unsuitable for completion of the study or place the patient at\n             potential risk from being in the study. For example, a malignancy, uncontrolled\n             hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895205", 
            "org_study_id": "PP-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Iron isomaltoside 1000", 
                "intervention_name": "Iron isomaltoside 1000", 
                "intervention_type": "Drug", 
                "other_name": "Monofer\u00ae"
            }, 
            {
                "arm_group_label": "Red blood cell transfusion", 
                "intervention_name": "Red blood cell transfusion", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Iron", 
                "Ferric Compounds"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer\u00ae) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia", 
        "other_outcome": [
            {
                "measure": "Change in anaemia symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to week 12"
            }, 
            {
                "measure": "Change in gastrointestinal symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "From Baseline to week 12"
            }
        ], 
        "overall_contact": {
            "email": "LLT@Pharmacosmos.com", 
            "last_name": "Lars Lykke Thomsen", 
            "phone": "+45 59 48 59 59"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Physical Fatigue", 
            "safety_issue": "No", 
            "time_frame": "From exposure to 12 weeks post-exposure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Hb concentration", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Change in p-ferritin", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Fatigue symptoms", 
                "safety_issue": "No", 
                "time_frame": "from baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Postpartum depression", 
                "safety_issue": "No", 
                "time_frame": "From week 1 to 3, 8 and 12"
            }, 
            {
                "measure": "Breastfeeding", 
                "safety_issue": "No", 
                "time_frame": "From exposure to 12 weeks post-exposure"
            }, 
            {
                "measure": "Number of adverse drug reactions (ADRs)", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Change in p-iron", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Change in p-transferrin", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Change in transferrin saturation (TSAT)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Change in reticulocyte count", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }, 
            {
                "measure": "Change mean reticulocyte haemoglobin content (CHr)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12"
            }
        ], 
        "source": "Pharmacosmos A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "BioStata", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Pharmacosmos A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}